| 适合移植的多发性骨髓瘤患者治疗研究进展 |
| |
| 引用本文： | 郭欢. 适合移植的多发性骨髓瘤患者治疗研究进展[J]. 白血病．淋巴瘤, 2014, 23(9): 564-566 |
| |
| 作者姓名： | 郭欢 |
| |
| 作者单位： | 100020,首都医科大学附属北京朝阳医院血液科 |
| |
| 基金项目： | 国家自然科学基金，首都临床特色应用研究专项资助课题 |
| |
| 摘 要： | 适合移植的多发性骨髓瘤（MM）患者的治疗通常采用三药方案诱导治疗后行造血干细胞采集.对于适合移植患者的标准预处理方案是大剂量美法仑方案.移植后行巩固治疗可提高缓解率.为了获得长期的疾病控制和改善总生存期,用硼替佐米或来那度胺（极高危患者二者联合）进行维持治疗是较合理的选择.随着新药在MM治疗中的应用,患者预后将会得到改善并获得长期的疾病控制.
|
| 关 键 词： | 多发性骨髓瘤 治疗方案 造血干细胞移植 |
Research progress of strategies for transplantation-eligible multiple myeloma patients |
| |
| Guo Huan. Research progress of strategies for transplantation-eligible multiple myeloma patients[J]. Journal of Leukemia & Lymphoma, 2014, 23(9): 564-566 |
| |
| Authors: | Guo Huan |
| |
| Affiliation: | Guo Huan(Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China) |
| |
| Abstract: | For transplantation-eligible multiple myeloma patients,induction treatment of triple drug regimens followed by the collection of hematopoietic stem cells is generally recommended.For transplantationeligible patients,high-dose melphalan remains the standard regimen.Consolidation after transplantation has shown an improvement in response rates.Maintenance therapy with bortezomib or lenalidomide （or both in very-high-risk patients） is a reasonable option for long-term disease control and improvement in overall survival.Application of new agents into therapy of multiple myeloma should result in improved outcomes and long-term disease control. |
| |
| Keywords: | Multiple myeloma Therapy protocols Hematopoietic stem cell transplantation |
| 本文献已被 维普 等数据库收录！ |
